Form 4: Mirum Pharma SVP Sells Shares for Tax After Equity Vesting

Mirum Pharmaceuticals' SVP, Global Controller, Jolanda Howe, reported the vesting of performance restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Jolanda Howe, SVP, Global Controller of Mirum Pharmaceuticals, Inc. (MIRM), reported changes in her beneficial ownership.
• On March 15, 2026, Howe acquired 2,658 shares of common stock through the vesting of performance restricted stock units (PRSUs).
• Also on March 15, 2026, Howe acquired an additional 6,000 shares of common stock from the vesting of other PRSUs.
• Following these acquisitions, Howe's direct beneficial ownership increased to 13,161 shares.
• On March 16, 2026, Howe disposed of 4,732 shares of common stock at a price of $91.9779 per share.
• This sale was specifically conducted to cover tax withholding obligations associated with the vesting of the performance restricted stock units.
• After the sale, Howe's direct beneficial ownership stands at 8,429 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there's a sale of shares, it's explicitly for tax purposes following equity vesting, which indicates successful performance and continued executive compensation.

Positives

• The vesting of performance restricted stock units indicates that performance targets were likely met, leading to equity compensation for the SVP, Global Controller.
• The acquisition of 8,658 shares (2,658 + 6,000) through vesting demonstrates continued alignment of management's interests with shareholders.

Negatives

• The sale of 4,732 shares, even for tax purposes, reduces the direct equity stake of a key executive in the company.

Future Outlook

The filing indicates future equity vesting for Jolanda Howe, with 1/3 of a tranche of performance restricted stock units scheduled to vest on March 15, 2027.

Industry Context

StockSavvy.ai notes that insider transactions, such as the vesting of equity and subsequent sales for tax purposes, are common occurrences in the biotechnology and pharmaceutical industry. These routine filings provide transparency into executive compensation and ownership changes, but typically do not reflect broader strategic shifts or competitive positioning within the industry.

Stakeholder Impact

• Shareholders: The vesting of PRSUs aligns executive incentives with shareholder value creation. The sale for tax purposes is a common, non-discretionary event and is unlikely to significantly impact shareholder sentiment.
• Employees: The successful vesting of performance-based equity awards can serve as a positive signal regarding the company's performance and compensation structure.

Next Steps

• The remaining 1/3 of the second tranche of performance restricted stock units held by Jolanda Howe is scheduled to vest on March 15, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of performance-based equity and a subsequent sale to cover tax obligations. Such transactions are common and generally do not indicate a change in the company's fundamental outlook or an executive's long-term conviction. Therefore, it does not provide sufficient new information to warrant a change from a 'hold' recommendation based solely on this filing.

Keywords

Mirum Pharmaceuticals, MIRM, Insider Transaction, Form 4, Jolanda Howe, SVP Global Controller, Equity Vesting, Performance Restricted Stock Units, Share Sale, Tax Withholding